<|ref|>table<|/ref|><|det|>[[130, 60, 870, 911]]<|/det|>
<|ref|>table_caption<|/ref|><|det|>[[87, 420, 110, 911]]<|/det|>
Table 1 PLOG with HKA14.5-9BRAE fusion, pan-tumor characteristics, response, and toxicity with trametinib   

<table><tr><td>Case</td><td>Age at diagnosis</td><td>Prior therapy</td><td>Prior treatment</td><td>Time on treatment</td><td>Functional response</td><td>Side effects</td></tr><tr><td>1</td><td>1.5-F</td><td>Histologic diagnosis:</td><td>Prior</td><td>Prior therapy</td><td></td><td></td></tr><tr><td>2</td><td>M, metalla oblongata</td><td>PR</td><td>PR</td><td>PR</td><td>PR</td><td>SD</td></tr><tr><td>3</td><td>PM, hypothalamic-</td><td>PR</td><td>PR</td><td>PR</td><td>PR</td><td>SD</td></tr><tr><td>4</td><td>PM, hypothalamic-</td><td>PR</td><td>PR</td><td>PR</td><td>PR</td><td>SD</td></tr><tr><td>5</td><td>PM, hypothalamic-</td><td>PR</td><td>PR</td><td>PR</td><td>PR</td><td>SD</td></tr><tr><td>6</td><td>PM, hypothalamic-</td><td>PR</td><td>PR</td><td>PR</td><td>PR</td><td>SD</td></tr><tr><td>7</td><td>PM, intratumorality</td><td>PR</td><td>PR</td><td>PR</td><td>PR</td><td>SD</td></tr><tr><td>8</td><td>PM, hypothalamic-</td><td>PR</td><td>PR</td><td>PR</td><td>PR</td><td>SD</td></tr><tr><td>9</td><td>PM, hypothalamic-</td><td>PR</td><td>PR</td><td>PR</td><td>PR</td><td>SD</td></tr><tr><td>10</td><td>PM, hypothalamic-</td><td>PR</td><td>PR</td><td>PR</td><td>PR</td><td>SD</td></tr><tr><td>11</td><td>GC, intratumorality</td><td>PR</td><td>PR</td><td>PR</td><td>PR</td><td>SD</td></tr></table>